Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
JAMA Dermatol, 2022.
Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group.
Read publication: JAMA Dermatol
Related
The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celeb...
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab a...
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the Br...
Contact Us
Find Us
The University of Manchester
First Floor Bright Building
Manchester Science Park
Manchester
M15 6GZ
0 Comments